Gregory Sephton is a Life Sciences and IP partner and Co-Head of Sterlington’s Intellectual Property practice. He has represented pharmaceutical, biotechnology and other technology innovators, including AstraZeneca, Novartis, Merck, Sanofi, and Regeneron in high-stakes patent litigation. He has extensive experience in high-value Hatch-Waxman patent litigations against generic drug challengers. He also has litigated bet-the-company patent cases involving biologics and lipid nanoparticle technology. Leveraging his litigation experience and deep technical industry knowledge, Gregory also counsels emerging and established life sciences and cosmetics companies on protecting, licensing, and monetizing their IP assets.
Gregory was a partner at Kramer Levin Naftalis & Frankel LLP and before that, was a partner at Fitzpatrick, Cella, Harper & Scinto (now Venable LLP) where he practiced for more than 20 years. He obtained his J.D. from Suffolk University, his Ph.D. in biochemistry from Brandeis University and his B.Sc. (Hons) in chemistry and biochemistry from the University of Toronto.
Partner, Co-Head Intellectual Property practice